BioCentury
ARTICLE | Company News

Sarepta bolsters gene therapy pipeline through deal with Lacerta

August 8, 2018 11:25 PM UTC

Sarepta Therapeutics Inc. (NASDAQ:SRPT) gained exclusive rights to an undisclosed preclinical gene therapy to treat Pompe disease from Lacerta Therapeutics Inc. (Alachua, Fla.), as well as options to two additional CNS gene therapy candidates.

Lacerta will receive $8 million up front and a $30 million equity investment from Sarepta. The company will also be eligible for development and sales milestones, plus single-digit royalties. ...

BCIQ Company Profiles

Sarepta Therapeutics Inc.

BCIQ Target Profiles

Dystrophin